Skip to content

Efficacy evaluation study on the therapeutic effect of Wenpi Qingwei Granule on non erosive reflux disease

Efficacy and Safety of Wenpi Qingwei Granules in Patients With Nonerosive Reflux Disease: a Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033061
Enrollment
Unknown
Registered
2020-05-19
Start date
2020-05-12
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonerosive Reflux Disease

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Subjects diagnosed with non-erosive reflux disease 2. Subjects aged between 18 and 70 years 3. Subjects diagnosed with syndrome of mixed cold and heat of traditional Chinese medicine 5. Subjects who voluntarily signed written informed consent form

Exclusion criteria

Exclusion criteria: 1. Subjects who have active peptic ulcer, gastrointestinal hemorrhage,severe dysplasia of gastric mucosa or suspected malignant change,achalasia or postoperative achalasia 2. Subjects who have organic diseases of the digestive system (such as acute and chronic pancreatitis, cirrhosis, etc.), or systemic diseases that affect the gastrointestinal motility, such as hyperthyroidism, diabetes mellitus over 10 years, chronic renal insufficiency, spirit (the score of SAS and SDS shows severe anxiety or depression), nervous system diseases, etc 3. Subjects who have severe organ diseases such as heart, liver and kidney (such as ALT, AST more than 2 times of normal value),hematopoietic system diseases and tumors 4.Subjects who have a history of anti reflux and other upper gastrointestinal operations 5.Pregnant or lactating women 6.Subjects who have a mentally ill, mentally and linguistically disabled, unable to describe their own symptoms and cooperat 7.Subjects who suspect or have a history of alcohol or drug abuse, or according to the judgment of the researcher, have other circumstances that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in the working environment and other situations that are likely to cause lost visits 8. Subjects who have a history of allergies to all the test drugs 9. Subjects who are participating in other clinical trials or have participated in other clinical trials within 4 weeks

Design outcomes

Primary

MeasureTime frame
Change of visual analogue (VAS) score of reflux symptoms and heartburn;

Secondary

MeasureTime frame
The secondary symptoms of Non-cardiogenic chest pain, epigastric pain, upper abdominal burning sensation, belching, cough, asthma, Pharyngeal different feeling were recorded;Change of traditional Chinese Medicine syndrome score;Change of gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) scale score;Change of patient ported outcome (PRO) for chronic gastrointestinal disease scale score;Change of self-rating anxiety scale (SAS) score;Change of self-rating depression scale (SDS) score;Change of EuroQol- 5 Dimension scale score;

Countries

China

Contacts

Public ContactHuang Shaogang

Guangdong Hospital of traditional Chinese Medicine

huangshaogang@gzucm.edu.cn+86 20-39318991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026